Why PCI Synthesis is Changing Its Name

Six months after we were acquired by French-based Novacap, PCI Synthesis remained very much the same company, only better.

Posted: December 19, 2018

API Manufacturing and Pharmaceutical Manufacturing

We’ve maintained our facilities and have plans to grow. We’ve not only kept our employees, we’ve been hiring additional staff and continue to invest in training and equipment to solve our sponsors’ analytical and drug substance development and manufacturing needs. And we now have integrated capabilities, resources and expertise that we couldn’t have provided back in the spring. Our sponsors can access additional chemistry expertise, solid state chemistry development, dual site processing, and substantial additional capacity for the commercialization of the next generation of Life Science products.

But one thing is changing.

Our name.

After more than 20 years, PCI Synthesis, a company that started out as PolyCarbon Industries, Inc. and evolved into a contract development and manufacturing organization (CDMO), is evolving again. As SEQENS, we join Novacap’s other related subsidiaries (PCAS, Uetikon and Proteus) to form a new global CDMO. SEQENS refers to our core synthesis activities, combined with the sequencing of molecules, competencies and technologies to take science to the next level.

The move positions SEQENS as an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and tailor-made solutions to its customers worldwide.

By consolidating our service offerings and our 24 manufacturing plants and three R&D centers in Europe, North America and Asia, SEQENS can better serve our sponsors and customers with global access to more than 3,200 employees, including hundreds of scientists, engineers and experts who will continue to ensure that the products we develop on your behalf are successfully transferred into production.

SEQENS will continue to support our sponsors’ and customers’ development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products. We also will continue to develop custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

The name change is effective today but we will roll out the name at our Newburyport and Devens locations and on our website. For the time being, however, you can continue to find us where we’ve always been, including at pcisynthesis.com. By the end of Q1 2019, we expect signage and websites will be updated to reflect the new corporate entity. (By the way, for what it’s worth, the Novacap name will disappear, too. Pierre Luzeau, the CEO of Novacap, will be the new CEO of SEQENS.)

Your team remains the same, including the phone numbers, although they will get new business cards and email addresses.

We are truly excited to be able to extend new services, equipment and resources to speed development.


About the Author

Ed Price CEO of PCI Synthesis
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...

Do you have questions? Talk to Ed.